araag2/HINT huggingface dataset:
Clinical trial NCT02156466 (phase 1, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: msb0010841, msb0010841, msb0010841, msb0010841, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Chronic plaque psoriasis for at least 6 months before screening

          -  Greater than or equal to (>=) 10% of BSA with plaques

          -  Psoriasis Area and Severity Index (PASI) >=12

          -  Static Physician's Global Assessment (sPGA) >=3 (where scores range from 0 [clear of
             disease] to 5 [severe disease]) at the screening and baseline visits

          -  Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          -  Any condition, including protocol-specified laboratory findings and findings in the
             medical history or in the pre-trial assessments which in the Investigator's opinion
             constitutes a risk or a contraindication for the subject's participation in the trial
             or that could interfere with the trial objectives, conduct or evaluation

          -  Currently having a form of non-plaque psoriasis as specified in the protocol

          -  Drug induced psoriasis

          -  Biological treatments as specified in the protocol, within 3 months prior to Day 1

          -  Systemic immunosuppressants or phototherapy as specified in the protocol, within 1
             month prior to Day 1

          -  Use of anti-coagulant medications and/or antiplatelet medications as defined in the
             protocol

          -  Use of aspirin as defined in the protocol

          -  Topical corticosteroid treatments other than low-strength or lower-mid strength
             corticosteroids on the face, scalp, axillae, and/or groin within 1 month prior to Day
             1

          -  Any previous treatment with an agent targeting interleukin (IL)-17, IL-12 and/or IL-23
             as specified in the protocol

          -  Other protocol defined exclusion criteria could apply
Clinical trial NCT02166229 (phase 1/phase 2, status: withdrawn)
Conditions: scleroderma, systemic sclerosis
ICD codes: L94.1, L94.0, M34.0, M34.89, M34.9, M34.82, M34.83, M34.81, M34.2
Drugs: divalproex sodium
SMILES: CCCC(CCC)C(O)=O
Reason stopped: 
    no subjects were enrolled.
  
Eligibility criteria:

        Inclusion Criteria:

          -  18 years of age or older

          -  Diagnosis of scleroderma as defined by the American College of Rheumatology (ACR)

          -  Presence of at least one digital manifestation occurring within the past 6 months,
             i.e. digital swelling/edema, digital ulcer, calcinosis cutis, restricted digital range
             of motion.

          -  Females of childbearing potential must take an oral contraceptive pill or use an
             equivalent birth control method during the study.

        Exclusion Criteria:

          -  Age <18 years old

          -  Ongoing use of high dose steroids (>10 mg/day) or unstable steroid dose in past 4
             weeks.

          -  An investigational drug or disease-modifying agent has been started within the past 6
             months, including but not limited to systemic corticosteroids, methotrexate,
             cyclosporine, azathioprine, cyclophosphamide, bosentan, mycophenolate mofetil,
             thalidomide, colchicine.

          -  Patient taking a medication with a significant drug-drug interaction with divalproex
             sodium, e.g. clomipramine and lamotrigine.

          -  Patient has another connective tissue disease or other condition that could affect
             rest pain and hand function, e.g. systemic lupus erythematosus, rheumatoid arthritis,
             or osteoarthritis.

          -  Patient has uncontrolled diabetes, chronic kidney disease, chronic hepatitis.

          -  Any of the following laboratory abnormalities at baseline: anemia (Hb < 8.5 gm/dL),
             thrombocytopenia with platelets <100,000, INR > 1.3 or known bleeding disorder,
             estimated GFR < 60 mL/min/1.73m2 or serum creatinine > 2.0 mg/dL, hyperbilirubinemia
             or elevation of AST or ALT

          -  Pregnancy or breast-feeding.

          -  History of severe depression (i.e. depression requiring medical treatment by a
             psychiatrist), suicidal ideation, epilepsy, bipolar disorder, or schizophrenia.
Clinical trial NCT02174822 (phase 1, status: completed)
Conditions: drug-drug interaction
ICD codes: Z71.51, E06.4, E23.1, E66.1, G25.1, G25.4, G25.61
Drugs: avp-786, paroxetine, duloxetine
SMILES: FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1, CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy adult males and females

          -  18 - 50 years of age

          -  BMI 18 - 30 kg/m2

        Exclusion Criteria:

          -  History or presence of significant disease

          -  History of substance abuse and/or alcohol abuse with the past 3 years

          -  Use of tobacco-containing or nicotine-containing products within 6 months

          -  Use of any prescription or the over-the-counter medications within 14 days
Clinical trial NCT02183675 (phase 1, status: completed)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: telmisartan/amlodipine, telmisartan/amlodipine/hctz, telmisartan/hctz
SMILES: CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O, CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O, NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
Eligibility criteria:

        Inclusion criteria:

          -  Healthy Japanese male subjects age >=20 and <=35 years; body weight: >=50 kg and <=80
             kg; body mass index: >=18.0 and <=25.0 kg/m2

          -  Without any clinically significant findings and complications on the basis of a
             complete medical history, including the physical examination, vital signs (blood
             pressure (BP), pulse rate (PR), body temperature), 12-lead electrocardiograms (ECGs),
             clinical laboratory tests

          -  Signed and dated written informed consent prior to admission to the trial in
             accordance with the Good Clinical Practice (GCP) and the local legislation.

        Exclusion criteria:

        - Any finding of the medical examination (including BP, PR and ECGs) deviating from normal
        and of clinical relevance.
Clinical trial NCT02187094 (phase 1/phase 2, status: completed)
Conditions: gastroparesis
ICD codes: K31.84
Drugs: tc-6499, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  A diagnosis of gastroparesis or symptoms consistent with gastroparesis for at least 6
             months (and Gastroparesis Cardinal Symptoms Index total score >22)

          -  Gastroparesis confirmed using the GEBT

          -  Type 1 or Type 2 diabetes with a Hemoglobin A1c ≤ 10%

          -  Fasting blood glucose (finger stick) ≤ 275 mg/dL prior to each GEBT

          -  Body Mass Index (BMI) ≤ 40

          -  Willingness to remain in clinical research facility for the protocol-required days of
             treatment and study procedures

          -  Willingness to use a double barrier method of birth control (except post-menopausal
             females)

          -  Able to understand study procedures and provide written informed consent

        Exclusion Criteria:

          -  History of abdominal surgery including gastric banding procedure

          -  Chronic parenteral feeding or feeding through a gastrostomy or jejunostomy tube

          -  Persistent daily vomiting

          -  A history of eating disorder

          -  Recent history of poor control of diabetes

          -  Acute severe gastroenteritis

          -  Have implanted or use any type of gastric electric stimulator

          -  Use of opiates, anticholinergic medications, GLP-1 mimetics or amylin analogs

          -  Use of medications potentially influencing upper gastrointestinal motility or appetite

          -  Allergies or intolerance to egg, wheat, milk, or algae

          -  Pregnant or lactating females

          -  Presence of a clinically significant medical condition at any time during the study

          -  Presence of clinically significant abnormalities in laboratory findings, physical exam
             findings or vital signs

          -  Participated in an investigational drug study within 30 days of screening
Clinical trial NCT02193490 (phase 1/phase 2, status: terminated)
Conditions: dry eye
ICD codes: H04.121, H04.122, H04.123, H04.129, H35.3111, H35.3112, H35.3121
Drugs: dnase, vehicle
SMILES: CC1=CC(O)=CC(C)=C1Cl
Reason stopped: 
    sponsor ceased sponsorship and terminated the research citing slow accrual of subjects in this
    clinical trial.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Aged 18 years or older.

          -  Capable of giving informed consent and does provide informed consent.

          -  Documented Dry Eye Disease for at least 6 months.

          -  Schirmer I <10

          -  Corneal/ conjunctival (Rose Bengal) staining ≥1

          -  Ocular symptoms must be considered as annoying or activity limiting (OSDI ≥13; mild).

          -  Women must be post-menopausal ≥ 1 year, or surgically sterilized. If not, a negative
             urine pregnancy test is required within 14 days of receiving her first dose of test
             medication (placebo/ study drug) along with definite evidence of contraceptive use
             during the duration of the study.

        Exclusion Criteria:

          -  Allergic to Deoxyribonuclease eye drops or any similar products, or excipients of
             Deoxyribonuclease eye drops 0.1%.

          -  Receiving or have received within 30 days any experimental systemic medication.

          -  Active ocular infection or ocular allergies.

          -  Any history of eyelid surgery or ocular surgery within the past 3 months.

          -  Corneal epithelial defect larger than 1 mm2 in either eye.

          -  The use of topical cyclosporine or corticosteroids within 2 weeks of enrollment

          -  Have active drug/alcohol dependence or abuse history
Clinical trial NCT02194374 (phase 1, status: withdrawn)
Conditions: leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: fludarabine, cyclophosphamide, rituximab, bendamustine
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    study closed with no enrollment due to unavailability of reagent.
  
Eligibility criteria:

        Inclusion Criteria:

          1. Patients with B cell CLL/SLL, age </= 85 years old, who have active disease that meets
             2008 IWCLL/NCI-WG criteria to initiate treatment.

          2. Patients who have failed at least one line of a standard treatment, including
             bendamustine, fludarabine, ibrutinib, or alemtuzumab and require treatment within 2
             years of completion of last treatment regimen or untreated patients with del17p by
             FISH (high-risk) who do not have an allogeneic stem cell transplant option.

          3. At least 21 days from last cytotoxic chemotherapy.

          4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) <2.

          5. Adequate hepatic function, defined as substance glutamate pyruvate transaminase (SGPT)
             <3 x upper limit of normal (ULN); serum bilirubin and alkaline phosphatase <2 x ULN,
             or considered not clinically significant by the study doctor or designee.

          6. Adequate renal function, defined as serum creatinine <2 x ULN.

          7. Able to provide written informed consent, and agree to practicing 2 forms of birth
             control during the study.

          8. Patients must have adequate cardiac function as indicated by New York Heart
             Association (NYHA) classification I or II AND left ventricular ejection fraction of
             >40% and adequate pulmonary function as indicated by room air oxygen saturation of
             >94%.

        Exclusion Criteria:

          1. Surface ROR1 expression by <5% of CLL cells.

          2. Positive beta-HCG in female of child-bearing potential defined as not post-menopausal
             for 12 months or no previous surgical sterilization or lactating females.

          3. Patients with known systemic allergy to bovine or murine products.

          4. Known positive serology for human immunodeficiency virus (HIV) or human anti-mouse
             antibody (HAMA).

          5. Active, uncontrolled autoimmune phenomenon autoimmune hemolytic anemia, idiopathic
             thrombocytopenic purpura (AIHA, ITP) requiring steroid therapy.

          6. Presence of >/= Grade 3 non-hematologic toxicity common terminology criteria (CTC)
             version 4 from the previous treatment.

          7. Concurrent use of investigational therapeutic agent.

          8. Prior allogeneic hematopoietic stem-cell transplantation if evidence of donor
             chimerism persists. Patients with exclusively autologous hematopoiesis are eligible.

          9. Refusal to participate in the long-term follow-up protocol (2006-0676).
Clinical trial NCT02195869 (phase 1/phase 2, status: completed)
Conditions: graft versus host disease
ICD codes: D89.810, D89.811, D89.813, D89.812
Drugs: ibrutinib
SMILES: NC1=NC=NC2=C1C(=NN2[C@@H]1CCCN(C1)C(=O)C=C)C1=CC=C(OC2=CC=CC=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Steroid dependent or refractory classic chronic GVHD disease.

          -  No more than 3 previous treatments for cGVHD.

          -  Receiving baseline systemic glucocorticoid therapy (at stable dose) for cGVHD at study
             entry.

          -  Men and women ≥18 years old.

          -  Karnofsky performance status ≥60.

        Exclusion Criteria:

          -  Known or suspected active acute GVHD.

          -  Current treatment with sirolimus AND either cyclosporine or tacrolimus.

          -  History of treatment with a tyrosine kinase inhibitor (eg, imatinib), purine analogs
             or other cancer chemotherapy in the 4 weeks prior to starting study drug.

          -  Currently active, clinically significant cardiovascular disease.

          -  Uncontrolled infections not responsive to antibiotics, antiviral medicines, or
             antifungal medicines or a recent infection requiring systemic treatment that was
             completed ≤14 days before the first dose of study drug.

          -  Progressive underlying malignant disease including post-transplant lymphoproliferative
             disease.

          -  History of other malignancy (not including the underlying malignancy that was the
             indication for transplant)

          -  Concomitant use of warfarin or other Vitamin K antagonists

          -  Known bleeding disorders or hemophilia.

          -  History of stroke or intracranial hemorrhage within 6 months prior to enrollment.

          -  Known history of human immunodeficiency virus (HIV) or active with hepatitis C virus
             (HCV) or hepatitis B virus (HBV).

          -  Concurrent use of a strong cytochrome P450(CYP) 3A inhibitor.
Clinical trial NCT02200848 (phase 1, status: terminated)
Conditions: chronic lymphocytic leukemia, small lymphocytic lymphoma
ICD codes: C91.11, C91.12, C91.10, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: lenalidomide, ibrutinib, rituximab
SMILES: NC1=NC=NC2=C1C(=NN2[C@@H]1CCCN(C1)C(=O)C=C)C1=CC=C(OC2=CC=CC=C2)C=C1
Reason stopped: 
    recruitment difficulties and toxicity
  
Eligibility criteria:

        Inclusion Criteria:

          -  Previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma that
             requires treatment

          -  No prior systemic treatment within 4 weeks of enrollment

          -  No corticosteroids within 2 weeks prior to study entry

          -  Measurable disease must be present

          -  No concomitant anti-cancer therapies

          -  ECOG status </= 2

          -  Patients with HIV infection are eligible

          -  Patients with treated CLL or SLL in CNS are eligible

          -  Non-pregnant and non-nursing

          -  Life expectancy greater than 60 days

          -  Adequate bone marrow, kidney and liver function

          -  No major surgery within 28 days or minor surgery within 5 days of starting treatment

        Exclusion Criteria:

          -  History od Richter's transformation

          -  History of prior allogeneic transplant

          -  Radioimmunotherapy within 1 year of enrollment

          -  Prior Bruton's tyrosine kinase inhibitor or lenalidomide

          -  History of allergic reactions to compounds similar to ibrutinib, lenalidomide or
             rituximab or hypersensitivity

          -  active or uncontrolled autoimmune hemolytic anemia or ITP

          -  Transfusion-dependent thrombocytopenia or bleeding disorders

          -  Active hepatitis B or C infections

          -  History of known Human Anti-Chimeric Antibody positivity

          -  History of erythema multiforme, toxic epidermal necrolysis, or Stevens-Johnson
             syndrome

          -  History of uncontrolled seizures

          -  Autoimmune disorder that requires active immunosuppression

          -  Stroke or intracranial hemorrhage within last 6 months

          -  History of congestive heart failure, myocardial infarction, unstable angina,
             uncontrolled arrhythmia or any Class 3 or 4 heart disease in the last 6 months

          -  No prior malignancy except if treated with curative intent with no active disease for
             more than 3 years; adequately treated non-melanoma skin cancer or cervical cancer in
             situ

          -  using warfarin or similar Vitamin K antagonists Unable to swallow capsules or disease
             significantly affecting gastrointestinal function or inhibiting small intestine
             absorption
Clinical trial NCT02205398 (phase 1, status: terminated)
Conditions: squamous cell carcinoma of head and neck (scchn), metastatic colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: inc280, cetuximab
SMILES: CNC(=O)C1=CC=C(C=C1F)C1=NN2C(CC3=CC=C4N=CC=CC4=C3)=CN=C2N=C1, [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female aged ≥ 18 years

          -  Metastatic colorectal cancer or head and neck squamous cell carcinoma

          -  c-MET positive (defined by c-MET IHC intensity score +2 in ≥ 50% of tumor cells and
             MET gene copy number ≥ 5 by FISH or IHC intensity score +3 in ≥ 50% of tumor cells)
             and K/NRAS WT status for mCRC patients only

          -  At least one previous line of treatment for the metastatic disease and the last
             treatment must have included cetuximab or panitumumab. Documentation of clinical
             benefit and subsequent progression on cetuximab or panitumumab as the most recent line
             of treatment is required for patients in the expansion part

          -  Measurable disease as per RECIST v1.1

          -  ECOG performance status ≤ 2

        Exclusion Criteria:

          -  Prior treatment with c-MET/HGF inhibitors

          -  History of severe reactions to cetuximab and/or panitumumab (except for G3 rash and G3
             hypomagnesaemia)

          -  History of acute or chronic pancreatitis

          -  Active bleeding within 4 weeks prior to screening visit

          -  Symptomatic brain metastases

          -  Feeding tube dependence

          -  Not adequate hematologic, renal and hepatic function
Clinical trial NCT02210663 (phase 1, status: completed)
Conditions: advanced solid tumors
ICD codes: K74.02, G47.22, H35.3133, H35.3134, H35.3113, H35.3114, H35.3123
Drugs: veliparib (abt-888)
SMILES: C[C@@]1(CCCN1)C1=NC2=CC=CC(C(N)=O)=C2N1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed malignant solid tumor, and any of the
             following: * Subjects with recurrent high grade serous ovarian cancer who completed or
             discontinued platinum based therapy; * Subjects with BRCA-mutated breast cancer who
             have received prior chemotherapy with anthracycline and/or taxanes; * Subjects with
             deleterious mutations of BRCA with advanced solid tumors who have received available
             standard therapies.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

          -  Life expectancy of greater than 12 weeks.

          -  Adequate organ and marrow function· Measurable or non-measurable disease.

        Exclusion Criteria:

          -  Major surgery and/or radiation within (<) 4 weeks prior to study enrollment.

          -  Chemotherapy or hormone therapy within (<) 4 weeks prior to study enrollment except
             for mitomycin C and nitrosoureas, in which case it is 6 weeks.

          -  Any investigational agents within (<) 4 weeks prior to study enrollment.

          -  Any anti-cancer Chinese medicine/herbal remedies within 14 days prior to study
             enrollment.

          -  Toxicities (with the exception of alopecia) from prior major surgery, radiation, or
             systemic chemotherapy have not recovered to less than grade 2.
Clinical trial NCT02219516 (phase 1, status: completed)
Conditions: gout
ICD codes: M10.9, M10.08, M10.00, M10.011, M10.012, M10.019, M10.021
Drugs: rdea3170
SMILES: CC(C)(SC1=CC=NC=C1C1=C2C=CC=CC2=C(C=C1)C#N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject has a body weight ≥ 50 kg (110 lbs.) and a body mass index ≥ 18 and ≤ 40
             kg/m2.

          -  Subject with renal impairment, as determined at Screening, with creatinine clearance
             as calculated by the Cockcroft-Gault formula of 60 to < 90 mL/min (mild impairment),
             30 to < 60 mL/min (moderate impairment), or 15 to < 30 mL/min (severe impairment), or
             a matched control subject (by age and body mass index) with a creatinine clearance of
             ≥ 90 mL/min.

          -  Subject has a Screening serum urate level ≥ 4.5 mg/dL and ≤ 10 mg/dL

        Exclusion Criteria:

          -  Subject has a history or clinical manifestations of significant metabolic,
             hematological, pulmonary, cardiovascular, gastrointestinal, neurologic, hepatic,
             renal, urological, or psychiatric disorders.

          -  Subject has a history or suspicion of kidney stones.

          -  Subject has a history of asthma.

          -  Subject has undergone major surgery within 3 months prior to Day 1.

          -  Subject has donated blood or experienced significant blood loss (> 450 mL) within 12
             weeks prior to Day 1 or gave a plasma donation